

September 1, 2016

Whom It May Concern

Company: KYORIN Holdings, Inc.
Representative: Minoru Hogawa
Representative Director, President
(Security Code: 4569, TSE 1st Sec.)
Contact: Shuji Miyaki
Director, Corporate Communication
President Office
Telephone: (0)3-3525-4707

Release of Montelukast tablets 10mg 「KM」 , Montelukast tablets 5mg 「KM」

TOKYO, Japan (September 1, 2016) —Kyorin Rimedio Co., Ltd. (Head office: Kanazawa City, Ishikawa, President: Michiro Oonota), a wholly owned subsidiary of KYORIN Holdings, Inc., announced the release of "Montelukast tablets 10mg, 5mg 「KM」 " (Active Ingredient: Montelukast Sodium) a treatment for bronchial asthma and allergic rhinitis.

This drug is an authorized generic drug for KIPRES and SINGULAIR, a treatment for bronchial asthma and allergic rhinitis drugs which are being sold by KYORIN Holdings' subsidiary KYORIN Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President : Mitsutomo Miyashita) and MSD K.K. (Headquarters: Chiyoda-ku, Tokyo, President: Jannie Oosthuizen).

After this release, in order to meet the needs of medical workers, Kyorin Rimedio Co., Ltd will cooperate with KYORIN Pharmaceutical Co., Ltd. and promote proper use of the product.

Kyorin Group, based on its corporate philosophy of "Contributing to better health", will continue striving to provide pharmaceuticals that meet the wide-ranging needs of patients and medical professionals.

< Product information >

- 1.Brand name : Montelukast tablets 10mg 「KM」 , Montelukast tablets 5mg 「KM」
2. Date of Launch in Japan : September 1, 2016
3. NHI Price : Montelukast tablets 10mg 「KM」 ¥101.80
Montelukast tablets 5mg 「KM」 ¥76.80
4. Manufacturer and seller : KYORIN Rimedio Co., Ltd.
5. Seller : KYORIN Pharmaceutical Co., Ltd.